Genscript Biotech Corporation
GNNSF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.92 | 0.70 | -0.40 |
| FCF Yield | -2.68% | -8.65% | -5.22% | -2.97% |
| EV / EBITDA | 39.02 | -16.54 | -15.58 | -17.64 |
| Quality | ||||
| ROIC | 0.19% | -14.22% | -21.14% | -20.77% |
| Gross Margin | 45.77% | 48.78% | 48.60% | 55.28% |
| Cash Conversion Ratio | 0.03 | 0.82 | 0.28 | 0.28 |
| Growth | ||||
| Revenue 3-Year CAGR | -1.69% | 17.99% | 16.98% | 23.19% |
| Free Cash Flow Growth | 83.75% | -37.29% | -18.12% | 1.67% |
| Safety | ||||
| Net Debt / EBITDA | 0.55 | 4.14 | 1.90 | 2.20 |
| Interest Coverage | 1.16 | -15.11 | -32.86 | -154.88 |
| Efficiency | ||||
| Inventory Turnover | 10.37 | 8.06 | 5.37 | 4.68 |
| Cash Conversion Cycle | 74.30 | 141.65 | 104.89 | 145.66 |